REG - Oncimmune Hldngs PLC - Notice of Full Year Results ended 31 May 2020

Oncimmune HoldingsAnnouncement

19/10/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201019:nRSS4022Ca

RNS Number : 4022C  Oncimmune Holdings PLC  19 October 2020

19 October 2020

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Notice of Full Year Results ended 31 May 2020

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, will be announcing its full year results for the year ended 31 May 2020
on Friday, 30 October 2020.

 

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief
Financial Officer, will host a presentation and conference call for analysts
at 11:30am GMT on the day of the results.

 

For conference call details please contact Alexander Davis of FTI Consulting
at Alexander.Davis@fticonsulting.com
(mailto:Alexander.Davis@fticonsulting.com) or 020 3727 1000.

 

The management team will also host on Investor Meet Company a live
presentation of the results on Friday, 30 October at 15:00 GMT.

 

•     The online presentation will be open to all existing shareholders
and potential new investors.

 

•     Questions can be submitted before the event via your Investor Meet
Company dashboard or at any time during the live presentation via the "Ask a
Question" function. Responses to the Q&A will be published at the earliest
opportunity on the Investor Meet Company platform.

 

•     Investor feedback can also be submitted directly to management
immediately following the event.

 

Access to Investor Meet Company is free and interested parties can register to
attend the presentation via the following link:
https://www.investormeetcompany.com/essensys-plc/register-investor
(https://www.investormeetcompany.com/essensys-plc/register-investor)

 

Attendees who have already registered on the Investor Meet Company platform to
meet the Company will automatically receive an invitation to the presentation.

 

For further information:

 

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

 

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

About Oncimmune

 

Our intimate understanding of the human immune system enables us to harness
its sophisticated response to disease to detect cancer earlier and to support
the development of better therapies.

 

The key to improving cancer survival is early detection and better selection
for therapy. As a company, we are driven by our passion to improve cancer
survival and give people extra time. Oncimmune's immunodiagnostic test,
EarlyCDT(®), can detect and help identify cancer on average four years
earlier than standard clinical diagnosis.

 

The unique combination of our core technology and understanding of the immune
system, powers our ImmunoINSIGHTS service; a proprietary platform that enables
life science organisations to optimise drug development and delivery, leading
to more effective, targeted as well as safer treatments for patients.

 

Oncimmune was founded in 2002 and launched its platform diagnostic technology
in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung
and EarlyCDT Liver. To date, over 200,000 tests have been performed for
patients worldwide. EarlyCDT Lung was also used in what is believed to be the
largest randomised controlled trial for the early detection of lung cancer
using biomarkers, the successful National Health Service (NHS) Early detection
of Cancer of the Lung ("ECLS") trial of 12,208 high-risk smokers in Scotland.
This trial demonstrated that EarlyCDT Lung reduced the incidence of patients
with late-stage lung cancer or unclassified presentation at diagnosis,
compared to standard clinical practice.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a
discovery research centre in Dortmund, Germany and a partner representative
office in Shanghai, China. Oncimmune joined the AIM Market of the London Stock
Exchange in May 2016 under the ticker ONC.L

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKVLFFBBLZFBQ